Inhibitors of IL-17A and its receptor have emerged as important targets for the treatment of autoimmune diseases (such as rheumatoid arthritis, psoriasis, etc.)and inflammatory bowel diseases (26). This evidence concerns the gene IL17A and psoriasis.